Results 121 to 130 of about 128,993 (222)
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
Introduction ABP 938 is being developed as a biosimilar to Eylea® (aflibercept reference product [RP]), an anti-vascular endothelial growth factor (VEGF) drug used in the management of retinal diseases.
Neungseon Seo +5 more
doaj +1 more source
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been recently reimbursed by AIFA.
Roberto Bergamaschi +2 more
openaire +2 more sources
Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market [PDF]
Kockaya, G., Tuna, E.
openaire +2 more sources
Pharmacovigilance, traceability and building trust in biosimilar medicines
The Medicines for Europe's Biosimilar Medicines Group met at the 2017 European Association of Hospital Pharmacists conference in France to discuss pharmacovigilance, traceability and building trust in biosimilar ...
Teun van Gelder +5 more
core +1 more source
Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Ran Jin +8 more
doaj +1 more source
A practical guide about biosimilar data for health care providers treating inflammatory diseases
Joseph Markenson,1,2 Daniel F Alvarez,3 Ira Jacobs,4 Carol Kirchhoff5 1Department of Rheumatology, 2Department of Medicine, Hospital for Special Surgery, New York, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc ...
Jacobs I +3 more
core
Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo +14 more
doaj +1 more source
Financial Analysis of Biosimilar Development Candidates: A Case Study on the US Biosimilar Business
This case study investigates the US biosimilar business and the approach that should be implemented when financially analyzing biosimilar development candidates.
Gutierrez, Bryan J.
core +2 more sources
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
223 ...
openaire +1 more source

